Blockbuster Patent Expiries Sparking Korean Generic War
This article was originally published in PharmAsia News
With patents for a series of global blockbuster drugs expiring this year, South Korean pharma firms are fiercely competing to grab bigger pieces of the domestic generic market. Amid an ongoing patent invalidation suit concerning BMS’s Baraclude, Dong-A ST has been banned from producing and selling its generic version until the patent expires, while the Korean pharma association has warned its members against illegal rebates amid intensifying generic competition.
You may also be interested in...
Among the Korean firms presenting at J.P. Morgan, Hanmi laid out its strategy for obesity and other core pipeline assets, Celltrion focused on its expanding biosimilar pipeline and China plans and LG Chem unveiled new R&D progress.
BeiGene licenses antibody therapeutics for Castleman’s disease and high-risk neuroblastoma.
After a year full of disappointing and unexpected events, the South Korean pharma sector is hoping for a turnaround in 2020, with expected biosimilar launches in global markets, progress in drug pipelines, large IPOs and implementation of a new law on cutting-edge biologics.